Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4

References

• Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33(27):2963–2974. doi:10.1200/JCO.2014.59.5827.
   PubMed Web of Science ®Google Scholar
• Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840–847. doi:10.1111/j.1365-2141.2008.07144.x.
   PubMed Web of Science ®Google Scholar
• Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol. 2012;156(6):730–743. doi:10.1111/j.1365-2141.2011.09024.x.
   PubMed Web of Science ®Google Scholar
• Sun XF, Zhen ZJ, Lui DG, et al. Improved treatment outcome in Chinese children and adolescents with Burkitt’s lymphoma and large cell lymphoma by using the modified B-non-Hodgkin’s lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol. 2006;77(5):365–371. doi:10.1111/j.1600-0609.2006.00735.x.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Bonifacio M, Tecchio C, et al. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol. 2012;87(1):22–25. doi:10.1002/ajh.22189.
   PubMed Web of Science ®Google Scholar
• Cremer M, Schwarzbich MA, Schöning T, Lisenko K, Ho AD, Witzens-Harig M. In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study. Ann Hematol. 2017;96(9):1573–1575. doi:10.1007/s00277-017-3044-4.
   PubMed Web of Science ®Google Scholar
• Kim H, Park ES, Lee SH, et al. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res Treat. 2014;46(4):358–365. doi:10.4143/crt.2013.047.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Lim MS, Gross TG, COG Non-Hodgkin Lymphoma Committee. Children’s Oncology Group’s 2013 blueprint for research: non-Hodgkin lymphoma. Pediatr Blood Cancer. 2013;60(6):979–984. doi:10.1002/pbc.24416.
   PubMed Web of Science ®Google Scholar
• Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18(8):1076–1088. doi:10.1016/S1470-2045(17)30444-8.
   PubMed Web of Science ®Google Scholar
• Strüßmann T, Fritsch K, Baumgarten A, et al. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. Br J Haematol. 2017;178(6):927–935. doi:10.1111/bjh.14802.
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Benner A, McClanahan F, et al. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. Br J Haematol. 2015;171(5):710–719. doi:10.1111/bjh.13652.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Little RF, Wilson WH. Update on Burkitt Lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1333–1343. doi:10.1016/j.hoc.2016.07.009.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859–1864. doi:10.1093/annonc/mdq677.
   PubMed Web of Science ®Google Scholar
• Wästerlid T, Jonsson B, Hagberg H, Jerkeman M. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma. 2011;52(11):2090–2096. doi:10.3109/10428194.2011.593274.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870–3879. doi:10.1182/blood-2014-03-563627.
   PubMed Web of Science ®Google Scholar
• Wästerlid T, Brown PN, Hagberg O, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24(7):1879–1886. doi:10.1093/annonc/mdt058.
   PubMed Web of Science ®Google Scholar
• Intermesoli T, Rambaldi A, Rossi G, et al. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013;98(11):1718–1725. doi:10.3324/haematol.2013.086827.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10036):2402–2411. doi:10.1016/S0140-6736(15)01317-3.
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia. 2013;27(5):1174–1177. doi:10.1038/leu.2012.255.
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167(3):394–401. doi:10.1111/bjh.13040.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–2743. doi:10.1182/blood-2006-07-036665.
   PubMed Web of Science ®Google Scholar
• Pillon M, Mussolin L, Carraro E, et al. Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated with the AIEOP LNH-97 protocol. Br J Haematol. 2016;175(3):467–475. doi:10.1111/bjh.14240.
   PubMed Web of Science ®Google Scholar
• Barth MJ, Goldman SC, Oesterheld J, et al. Reduced burden of therapy in intermediate risk mature B-cell non-Hodgkin lymphoma (B-NHL): preliminary results of the reduced burden of oncologic therapy (REBOOT) trial. Pediat Blood Cancer. 2016;63:S50. Abstract.
   Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. World Medical Association. JAMA. 2013;310:2191–2194.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–2302. doi:10.1182/blood-2002-04-1199.
   PubMed Web of Science ®Google Scholar
• Poirel HA, Cairo MS, Heerema NA, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009;23(2):323–331. doi:10.1038/leu.2008.312.
   PubMed Web of Science ®Google Scholar
• Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7:332–339.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2004;105(3):948–958. doi:10.1182/blood-2004-03-0973.
   PubMed Web of Science ®Google Scholar
• Mukhtar F, Boffetta P, Risch HA, et al. Survival predictors of Burkitt’s lymphoma in children, adults and elderly in the United States during 2000-2013. Int J Cancer. 2017;140(7):1494–1502. doi:10.1002/ijc.30576.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. J Clin Oncol. 2016;34:10507. Abstract.
   Web of Science ®Google Scholar